Back

Silencing TTR, distinct signals: safety profiles of small interfering RNA therapies in amyloidosis

9 May 2026 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Advances in amyloidosis and hypertrophic cardiomyopathy: from diagnosis to treatment Pharmacotherapy Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Mrs Joyce Gu

Erie (United States of America)

6 More presentations in this session

Presentation thumbnail
Acute administration of EDG-15400, a novel cardiac sarcomere modulator, improves left ventricular compliance and cardiac reserve in a genetic mini-pig model of HCM with relevance to HFpEF
Doctor C. Emter (Boulder, US)
Abstract Slides Video
Presentation thumbnail
Prevalence and prognostic implications of frailty and other geriatric conditions in patients with transthyretin amyloid cardiomyopathy. The AMYLO-FRAIL study.
Doctor M. Antunez-Ballesteros (Coruna, A, ES)
Abstract Slides Video
Presentation thumbnail
Tafamidis in women with wild-type transthyretin cardiac amyloidosis: an international cohort study
Doctor P. Debonnaire (Brugge, BE)
Abstract Slides Video
Presentation thumbnail
Treatment with transthyretin-lowering RNA interference therapeutics is not associated with ocular or other clinical events due to vitamin A reduction: pooled analysis of vutrisiran and patisiran data
Doctor M. Maurer (New York, US)
Abstract Slides Video
Presentation thumbnail
Transthyretin gene silencing therapy in Val50Met familial amyloid polyneuropathy with associated cardiomyopathy
Doctor P. Monteiro (Porto, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Advances in amyloidosis and hypertrophic cardiomyopathy: from diagnosis to treatment

The Event

Event poster

Heart Failure 2026

9 May - 12 May 2026
You may be interested in
thumbnail
Congress Presentation
Treatment with transthyretin-lowering RNA interference therapeutics is not associated with ocular or other clinical events due to vitamin A reduction: pooled analysis of vutrisiran and patisiran data
thumbnail
Congress Presentation
Safety profile of acoramidis in cardiac amyloidosis: insights from post-marketing pharmacovigilance data
thumbnail
Congress Presentation
Outcomes with early access tafamidis in patients with variant transthyretin amyloid cardiomyopathy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources